Trial Profile
An Open‐Label, Randomized Comparison of Elvitegravir‐Cobicistat‐Tenofovir Alafenamide-Emtricitabine Versus Efavirenz‐Tenofovir Disoproxil Fumarate‐Lamivudine in Patients Starting Antiretroviral Therapy on the Day of HIV Diagnosis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide (Primary) ; Efavirenz/lamivudine/tenofovir disoproxil fumarate
- Indications HIV infections
- Focus Therapeutic Use
- 16 Mar 2020 Planned initiation date changed from 1 Mar 2018 to 1 May 2018.
- 16 Mar 2020 Planned End Date changed from 1 Aug 2019 to 1 Jul 2020.
- 16 Mar 2020 Planned primary completion date changed from 1 Aug 2019 to 1 May 2020.